Aydemir Gozde Aksoy, Demirok Gulizar, Eksioglu Umit, Yakin Mehmet, Ornek Firdevs
Department of Ophthalmology, Adiyaman University Training and Research Hospital, Adiyaman, Turkey.
Department of Ophthalmology, Health Sciences University, Ankara Training and Research Hospital, Ankara, Turkey.
Beyoglu Eye J. 2021 Feb 15;6(1):24-30. doi: 10.14744/bej.2021.76376. eCollection 2021.
This study examined the effect of antiglaucomatous drops with different preservatives on corneal biomechanics using the ocular response analyzer (ORA) (Reichert Technologies, Inc., Depew, NY, USA).
Patients using antiglaucomatous medical treatment containing a single agent combined with a preservative for at least 1 year who underwent a control examination between January and December 2017 at a glaucoma unit were included in this retrospective study. The patients were divided into 5 groups according to the antiglaucomatous agent and preservative ingredients. Measurements were taken with the ORA and compared with a control group.
A total of 83 eyes treated eyes were included and analyzed. Thirty-three eyes of 33 patients were treated with latanoprost+benzalkonium chloride (BAC), 17 eyes of 17 patients were treated with travoprost+polyquad, 7 eyes of 7 patients were treated with bimatoprost+BAC, 18 eyes of 18 patients were treated with brimonidine+purite, 8 eyes of 8 patients were treated with brimonidine+BAC. A control group of 23 eyes of 23 healthy patients was also assessed for comparison. A significant decrease in corneal hysteresis (CH) and corneal resistance factor (CRF) was seen in the patients using bimatoprost+BAC and brimonidine+BAC when compared with the control group. Evaluation of the bimatoprost+BAC group and the latanoprost+BAC group revealed that the CH and the CRF was significantly lower in the group using bimatoprost+BAC (p<0.01).
It has been reported that CH is a more important prognostic marker than central corneal thickness in glaucoma patients. Loss of visual field progresses faster in eyes with a low CH. Both preservatives and the active antiglaucomatous agents in medications can affect CH. Variation in CH in patients using antiglaucomatous drops over a long period is important in both the progression and follow-up of the disease.
本研究使用眼反应分析仪（ORA）（美国纽约州迪皮尤市瑞奇泰克公司），检测了含不同防腐剂的抗青光眼滴眼液对角膜生物力学的影响。
本回顾性研究纳入了2017年1月至12月期间在青光眼专科接受对照检查、使用含单一药物及防腐剂的抗青光眼药物治疗至少1年的患者。根据抗青光眼药物及防腐剂成分，将患者分为5组。使用ORA进行测量，并与对照组进行比较。
共纳入并分析了83只接受治疗的眼睛。33例患者的33只眼睛接受了拉坦前列素+苯扎氯铵（BAC）治疗，17例患者的17只眼睛接受了曲伏前列素+聚季铵盐治疗，7例患者的7只眼睛接受了比马前列素+BAC治疗，18例患者的18只眼睛接受了溴莫尼定+泊利噻嗪治疗，8例患者的8只眼睛接受了溴莫尼定+BAC治疗。还评估了23例健康患者的23只眼睛作为对照组进行比较。与对照组相比，使用比马前列素+BAC和溴莫尼定+BAC的患者角膜滞后（CH）和角膜阻力因子（CRF）显著降低。对比马前列素+BAC组和拉坦前列素+BAC组的评估显示，使用比马前列素+BAC的组中CH和CRF显著更低（p<0.01）。
据报道，在青光眼患者中，CH是比中央角膜厚度更重要的预后指标。CH较低的眼睛视野丧失进展更快。药物中的防腐剂和活性抗青光眼药物均可影响CH。长期使用抗青光眼滴眼液的患者CH的变化在疾病进展和随访中均具有重要意义。
